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Abstract
Background: Influenzanet was launched in several European countries to monitor influenza-like illness during flu seasons with
the help of volunteering participants and Web-based technologies. As in the case of developing fields, ethical approaches are not
well developed in the collection, processing, and analysis of participants’ information. Existing controversies and varying national
ethical regulations can, thus, hamper efficient cross-border research collaboration to the detriment of quality disease surveillance.
Objective: This scoping review characterizes current practices on how ethical, legal, and social issues (ELSIs) pertinent to
research ethics are handled by different Influenzanet country groups to analyze similarities and identify the need for further
harmonization of ethical approaches.
Methods: A literature search was carried out on PubMed, Web of Science, Global Digital Library on Ethics, and Bioethics
Literature Database to identify ELSIs for Influenzanet country platforms. Only English-language papers were included with
publication dates from 2003 to 2017. Publications were screened for the application of bioethics principles in the implementation
of country platforms. Additional publications gathered from the Influenzanet Consortium website, reference screening, and
conference proceeding were screened for ELSIs.
Results: We gathered 96 papers from our search methodology. In total, 28 papers that mentioned ELSIs were identified and
included in this study. The Research Ethics Committee (REC) approvals were sought for recruiting participants and collecting
their data in 8 of 11 country platforms and informed e-consent was sought from participants in 9 of 11 country platforms.
Furthermore, personal data protection was ensured throughout the Consortium using data anonymization before processing and
analysis and using aggregated data.
Conclusions: Epidemics forecasting activities, such as Influenzanet, are beneficial; however, its benefits could be further
increased through the harmonization of data gathering and ethical requirements. This objective is achievable by the Consortium.
More transparency should be promoted concerning REC-approved research for Influenzanet-like systems. The validity of informed
e-consent could also be increased through the provision of a user friendly and standard information sheet across the Consortium
where participants agree to its terms, conditions, and privacy policies before being able to fill in the questionnaire. This will help
to build trust in the general public while preventing any decline in participation.
(JMIR Public Health Surveill 2018;4(4):e67)   doi:10.2196/publichealth.9616
JMIR Public Health Surveill 2018 | vol. 4 | iss. 4 | e67 | p.1http://publichealth.jmir.org/2018/4/e67/
(page number not for citation purposes)
Geneviève et alJMIR PUBLIC HEALTH AND SURVEILLANCE
XSL•FO
RenderX
KEYWORDS
communicable diseases; influenza, human; public health surveillance; research ethics; web-based technologies; mobile phones;
smartphone; participatory surveillance
Introduction
Web-based technologies have become an integral part of public
health surveillance over the last 2 decades [1]. It is estimated
that 4.3 billion people globally will have mobile broadband
subscriptions by the end of 2017 [2]. Their ubiquitous
availability allows volunteer citizens to engage in disease
detection through digital means [3]. Real-time granular health
data are, thus, collected from volunteering participants (eg, via
mobile phones with global positioning), supplementing the big
data collected by public health authorities and laboratories [3,4].
Combining these different data sources allows earlier and finer
spatial detection of public health threats than traditional
surveillance systems, permitting more appropriate preventive
and mitigating measures to be deployed [4]. A successful
example of such disease digital detection is the European
Influenzanet Consortium.
Every year in Europe, seasonal flu brings its share of morbidity
and mortality among vulnerable groups (eg, the elderly) and a
rise in associated medical costs [5]. Infection with influenza
virus is hard to diagnose without virological confirmation, and
public health authorities usually rely on influenza-like illness
(ILI) as a surveillance indicator for outbreaks [6]. This
surveillance program is carried out by the European Influenza
Surveillance Network (EISN), which is coordinated by the
European Centre for Disease Control [7]. Since 2008, EISN has
relied on ILI reports by general practitioners from national
sentinels in its 30 European Union and European Economic
Area countries [8]. However, this traditional surveillance system
is biased by the use of nonuniform case definitions for ILI by
the Member States and depends on the rate at which patients
seek medical care from general practitioners, thereby reflecting
only medically attended ILI incidence rates [9-11]. The general
practitioner consultation rate is itself dependent on several
factors that include the time delay between the onset of
symptoms and health complications, the need of certificates
from general practitioners for prolonged work absenteeism
owing to illness, types of health insurance, and health care
systems [12]. Thus, there is a non negligible underestimation
of the real disease burden of influenza outbreaks [13]. The
current limitations of EISN led to the development of
Influenzanet, an innovative ILI surveillance network based on
the active participation of public volunteers and the use of
Web-based technologies to report cases of ILI, complementing
data gathered by EISN [12,14].
The Influenzanet Consortium was launched in 2003 in the
Netherlands and the Flemish part of Belgium [6]. Denmark,
France, Ireland, Italy, Portugal, Spain, Sweden, Switzerland,
and the United Kingdom have also joined this surveillance
network [15]. However, very recently in 2017, the
Netherlands-Belgium platforms have ceased their activities
because of lack of funding, which undermines the excellent
work done by these platforms in promoting the ILI surveillance
for 15 years in their countries. The platforms will resume their
activities if funding is made available by May 2018. Otherwise,
the platforms will terminate their activities permanently [16].
Public volunteers are usually recruited via mass media, and
there are no exclusion criteria for registration (except for
Sweden) [17-19]. At registration, volunteers fill in an intake
questionnaire and afterwards, receive a weekly reminder by
email to fill in an ILI-related symptom questionnaire [6].
Importantly, the absence of symptoms is also declared. In
addition, participants are allowed to indicate symptoms of ILI
for other household members in an attempt to increase the data
collection for children and elderly individuals [17].
Influenzanet offers numerous advantages over EISN, including
the following: ILI incidence rates are extrapolated from both
medically attended and unattended patients, real-time
disease-monitoring capability through the citizen participation,
flexibility to changes without disturbance of the overall system
functionality, uniform data collection allowing direct
comparisons between countries, comparatively lower running
costs, easier to increase scalability, and participant empowerment
through information on prevention strategies and disease activity
at local and national levels [11,13,17,20].
Nonetheless, Influenzanet also has some disadvantages,
including the self-selection bias of participants (eg,
underrepresentation of younger and older age groups), absence
of virological confirmation of influenza cases, recruitment and
motivation of participants to continuously donate their data for
surveillance are problematic (eg, limited sample sizes in some
countries), and limited amount and complexity of data that can
be collected to ensure the continued use of platforms by
participants [11,13,17].
This approach for monitoring disease involves the collection of
information about users that affects their risks of influenza or
complication from influenza; this information includes the
demographic data, vaccination status, presence of certain
medical conditions (eg, diabetes mellitus), use of food
complements, daily activities, and household composition (eg,
presence of children) [21]. Moreover, some national platforms
have developed mobile apps as additional data collection tools;
for instance, the Swiss mobile app gathers useful supplementary
data through smartphone sensors (eg, inbuilt movement sensors
to test for an association between the physical activity level of
participants and the risk of ILI) or smartphone features (eg, test
for an association between the psychological profile of
participants, inferred via the list of apps installed, and attitude
toward vaccination; Grippenet Switzerland, email
communication, November 29, 2017). This complements the
data gathered from questionnaires, allowing to answer innovative
research questions and implement rational public health
strategies while maintaining high privacy protection measures;
for example, only highly aggregated and summarized versions
of the data are transmitted for analysis, whereas the bulk of data
is stored locally on participants’ smartphones. Moreover, mobile
app data will not be shared with the rest of the Consortium until
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a framework for data sharing is set up. Nonetheless, Influenzanet
data can be valuable and sensitive information. Thus, collecting
such information poses ethical, legal, and social issues (ELSIs),
in particular, if the collected data could be used for secondary
research purposes or in the event of a cyber attack leading to
data leakage.
As it is commonly the case for developing fields, ethical
approaches are not yet well developed in the collection (here
through Web-based technologies), processing, and analysis of
participants’ information. Existing controversies can, thus, be
the cause of additional barriers to efficient collaboration.
Furthermore, although research collaboration and comparability
of data are important because epidemics do not stop at national
borders, varying ethical regulations at national levels can hamper
collaboration between countries. Additionally, a number of new
ethical issues raised by Influenzanet-like activities do not or
only partially fit traditional evaluation categories used by
Research Ethics Committees (RECs) for clinical trials or
data-based research. This scoping review aims to discuss ELSIs
of these participatory surveillance systems. First, we
characterized the current practices using findings from the
literature search where we compared how issues related to
research ethics are being handled by different Influenzanet
country groups to analyze similarities and identify the need for
further harmonization of ethical approaches. Thereafter, we
carried out an ELSI analysis to suggest ways to strengthen them
to lay the ground for expanding the capacity and positive impact
of such systems in the future.
Methods
For this review, we followed the methodological guidance
provided for conducting a scoping review [22]. Four databases,
namely, PubMed, Web of Science (all databases), Global Digital
Library on Ethics, and BELIT (Bioethics Literature Database)
were searched to identify ELSIs for the national platforms of
the Influenzanet Consortium.
We used the following key terms: Influenzanet, De Grote
Griepmeting, Flusurvey, Gripenet, Grippenet, Hälsorapport,
Influmeter, and Influweb. Only English-language papers with
publication dates from the last 15 years (2003-2017) were
included. The search started from 2003 because the first
Influenzanet national platform, De Grote Griepmeting, was
launched in this year.
In line with the conception of modern research ethics, we
searched publications related to Influenzanet for the use and
application of ethical principles [23,24] in the implementation
of these national platforms; these principles are as follows:
respect for autonomy (respect the decision-making capacity of
Influenzanet participants through the provision of a: an informed
consent and b: opt-out option); beneficence (direct and indirect
benefits provided to Influenzanet participants via Web-based
information on the study); nonmaleficence (prevention of
informational harm to Influenzanet participants such as personal
data protection measures, for example, anonymization of
personal data); and justice (ensuring open and nondiscriminative
participation of users to the Influenzanet network to ensure
fairness in the distribution of benefits and risks) [25]. In addition,
we evaluated the presence of ethical approval by an ethics
committee to balance the benefits and risks to participants, future
patients, or society. Additional publications found on the
Influenzanet Consortium website [15] were gathered and
screened for ELSIs as well. Furthermore, reference lists of
included publications were searched for additional studies. Only
publications mentioning at least one of these 6 ELSI components
were included.
The included full-text papers were screened and analyzed
independently by 2 review authors (LDG and TW) to ensure
that they met the inclusion criteria of having information on the
desired ELSI components previously described. Discrepancies
between the 2 review authors were solved through discussion.
Figure 1 illustrates the methodological process behind the
selection and inclusion of publications for this review based on
the PRISMA framework for systematic reviews and
meta-analyses [26]. When the gathered literature did not provide
sufficient information on some national platforms, country
members of the Influenzanet Consortium were contacted either
through email or the coordinator of the Consortium to provide
additional details and to assess the veracity of the information
gathered on their respective platforms.
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Figure 1. The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flowchart of study selection. ELSI: ethical, legal, and
social issues.
Results
The original literature search, carried out on September 11 and
repeated on October 10 2017 in the databases mentioned above,
identified a total of 66 potentially relevant papers (Table 1) on
the Influenzanet Consortium and its national platforms (eg, De
Grote Griepmeting for the Netherlands and Belgium, Flusurvey
for the United Kingdom and Ireland, Gripenet for Portugal and
Spain, Grippenet for France and Switzerland, Hälsorapport for
Sweden, Influmeter for Denmark, and Influweb for Italy). No
papers on Influenzanet were found on the Global Digital Library
on Ethics and BELIT.
After the removal of duplicates (n=29), 37 papers were
considered for this study. Among these 37, 4 were datasets, 5
included supporting information to other papers in the list (eg,
tables and figures), 2 papers were in other languages (French
and Swedish), and 2 were meeting abstracts; these 13 papers
were excluded. The remaining 24 full-text papers were then
screened for 6 ELSI components (informed e-consent obtained
from participants; ability of participants to opt out from the
study at any time; Web-based information on national platform
and influenza; personal data protection measures, for example,
anonymization and abiding to the national regulations on
privacy, data collection, and treatment; open and
nondiscriminative participation; and ethical approval by an REC
or other competent entity). Only 16 of the 24 papers addressed
some ethical, legal, and social components (eg, ethical approval
by RECs, informed consent, etc).
Our search of the Influenzanet Consortium website [15] resulted
in an additional 28 publications. After the removal of duplicates
(n=14), 14 publications were considered for a detailed review
of their ELSI components. Notably, 10 of the 14 papers
addressed some ethical, legal, and social components.
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Table 1. Initial search results (date of search: September 11, 2017 and October 10, 2017).
Results found in all Web of Science databases (n=44), nResults found in PubMed (n=22), nSearch terms used
1610European network: Influenzanet
National platforms
00De Grote Griepmeting
73Flusurvey
11Gripenet
126Grippenet
20Hälsorapport
11Influmeter
51Influweb
Overall, 2 additional publications (retrieved from reference
screening and a conference proceeding) were included, leading
to a total of 28 papers included in our analysis, as seen in Figure
1. Table 2 reports on these 28 papers and summarizes the
presence or absence of the ELSI components for each paper
reviewed. However, Table 2 should be interpreted cautiously
because the presence of some ELSI components does not
automatically apply to all country platforms in
noncountry-specific publications.
The Influenzanet country-specific information in Table 3 was
collated from publications gathered in the literature search
(Table 2) and additional information provided by country
representatives. The information in Table 3 was subsequently
double checked, updated, and corrected by country
representatives (in many cases, authors of papers themselves)
through the help of the supervisor of the Consortium who
communicated our findings. This verification step was important
to prevent inaccuracies resulting from the misinterpretation of
the literature because the absence of an ELSI component in a
publication does not automatically imply that it was not
addressed by the platform(s) and temporal evolution of these
platforms, where ELSI components might change over time.
Only 3 of 11 national platforms (Belgium-the Netherlands and
Denmark) did not seek ethical approval by REC before the
launch of their platforms. The Swiss national platform [45] has
obtained ethical approval for the launch of its mobile app before
the start of the flu season 2017/2018. Registration and
participation to the national platforms were open and
nondiscriminative to all residents of the respective countries
[12,14], except for the Swedish platform, where participation
is through invitations only [17,18]. The Web-based information
on the study was provided to all Influenzanet participants and
informed electronic consents were obtained from participants
in 9 of 11 national Influenzanet platforms. The electronic
consent or so-called “e-consent” commonly used in studies
without face-to-face contact, but where communication is
entirely taking place via Web-based technologies, is another
exception to, or adaptation of, traditional informed consent.
Influenzanet uses this type of e-consent, where participants
through a few clicks on a screen agree to the terms, conditions,
and privacy policies of the research project.
The Belgium-Dutch and Danish platforms were the only
exceptions where an informed e-consent was not legally required
for participation (Influmeter, email communication, August 10,
2017) [6,20,21]. All Influenzanet users were allowed to
withdraw from the research at any time. Participant identifiers
used in Influenzanet (eg, pseudonyms and email addresses)
were stored separately from the questionnaire data and not used
during the data processing and analysis phases. Personal data
from participants were, thus, anonymized before processing or
analysis, which were performed at the aggregate level in all
national platforms [14].
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Table 2. A list of included studies (n=28) with ethical, legal, and social issue components (with ethical approval of study). All platforms listed by each
paper do not satisfy the ethical, legal, and social issue components equally.
Ethical, legal, and social issue componentsPlatform(s) concernedAuthor (year)
Personal data
protection
measures
Opt out
from
study
Informed
e-consent
Web-based
information
sheet
Open and non-
discriminative
participation
Research
ethics com-
mittee
✓✓✓UKaAdler et al (2014) [27]
✓✓✓✓✓BEb, FRc, ITd, NLe, PTf,
SEg, UK
Bajardi et al (2014) [28]
✓✓✓✓BE, FR, IT, NL, PT, SE, UKBajardi et al (2014) [29]
✓✓✓✓✓UKBrooks-Pollock et al (2011) [19]
✓✓✓✓✓BE, FR, IT, NL, PT, SE, UKCantarelli et al (2014) [14]
✓✓✓FRDebin et al (2013) [30]
✓✓FRDebin et al (2014) [10]
✓✓UKEames et al (2012) [31]
✓✓✓✓UKEames et al (2012) [32]
✓✓BE, NLFriesma et al (2009) [5]
✓✓✓BE, FR, IT, NL, PT, UKGuerrisi et al (2016) [33]
✓✓DKhKjelso et al (2016) [20]
✓✓✓✓✓BE, DK, FR, IEi, IT, NL,
PT, SE, ESj, UK
Koppeschaar et al (2017) [17]
✓✓BE, NLLand-Zandstra et al (2016) [34]
✓✓✓✓✓FRLoubet et al (2016) [35]
✓✓✓✓✓FRLoubet et al (2016) [36]
✓✓✓NLMarquet et al (2006) [21]
✓✓ITPaolotti et al (2010) [37]
✓✓✓UKPeppa et al (2017) [38]
✓✓ITPerrotta et al (2017) [39]
✓✓ITPerrotta et al (2017) [40]
✓✓SEPini et al (2017) [18]
✓✓NLSmolderen et al (2007) [41]
✓✓✓UKTilston et al. (2010) [42]
✓✓BE, NL, PTvan Noort et al (2007) [11]
✓✓BE, IT, NL, PTvan Noort and Stollenwerk
(2008) [43]
✓✓BE, IT, NL, PTvan Noort et al (2015) [9]
✓✓✓BEVandendijck et al (2013) [6]
aUK: United Kingdom.
bBE: Belgium.
cFR: France.
dIT: Italy.
eNL: the Netherlands.
fPT: Portugal.
gSE: Sweden.
hDK: Denmark.
iIE: Ireland.
jES: Spain.
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Table 3. The ethical, legal, and social dimensions of Influenzanet national platforms (with research ethics approval of study).
Personal data
protectiona
Ability to opt
out from the
study
Informed
e-consent
Web-based
information
sheet
Open and non-
discriminative
participation
Research ethics approval
of study
Date of creationNational platform
✓✓—✓✓—b2003Belgium (Flanders)
✓✓✓c✓✓—c2013Denmark
✓✓✓✓✓✓2012France
✓✓✓✓✓✓2013Ireland
✓✓✓✓✓✓2008Italy
✓✓✓✓✓✓2005Portugal
✓e✓✓d✓✓✓d2012Spain
✓✓✓✓—✓2011Sweden
✓✓✓✓✓✓2016Switzerlandf
✓✓—g✓✓—2003The Netherlands
✓✓✓✓✓✓2009United Kingdom
aData anonymization before processing and analysis.
bNot applicable.
cInflumeter, email communication, August 10, 2017-September 07, 2017.
dGripeNet Spain, email communication, August 10, 2017.
eInformation obtained from the Spanish national platform [44].
fSwiss Influenzanet platform [45]. Grippenet Switzerland, email communication, September 12, 2017.
gDe Grote Griepmeting The Netherlands, email communication, January 10, 2018.
Discussion
Principal Findings
To the best of our knowledge, this is the first scoping review
examining the similarities and differences in the implementation
of research ethics for the country platforms of Influenzanet. Our
comparative tables highlight the need for further clarification
and harmonization of these ethical issues pertinent to citizens
engaging in the digital disease surveillance across the
Consortium. A number of ELSIs are similarly organized in the
Consortium, for instance, participation is open and
nondiscriminative to all residents of these countries (except for
Sweden for representativeness and comparison purposes [17]),
study information is provided to all participants, and they are
free to opt out from the study. However, a number of ELSIs are
also addressed differently; for instance, REC approvals and
informed e-consent were sought for recruiting participants and
collecting their data in 8 of 11 and 9 of 11 platforms,
respectively. The following sections of the discussion will
highlight the discrepancies seen in the implementation of
research ethics for different country platforms.
Overall, 8 platforms of the Consortium obtained REC approval
before the start of their studies. However, it is not known how
national RECs judged and approved their respective studies;
for instance, they could have considered the gathered personal
health-related data from participants to be fully anonymized for
which no informed consent is required or considered studies to
be human subject research. In the latter case, RECs would need
to evaluate if the balance between potential benefits and risks
for study participants is favorable and ensure that participants
received adequate information on these risks and benefits. Our
comparative table shows that all country platforms where REC
approvals had been sought obtained informed e-consents from
participants; this seems to indicate that these national RECs
consider this type of citizen participatory research as human
subject research and that e-consent is considered a valid form
of consent in this context. The regional REC in Geneva approved
the implementation of the Swiss platform and the launch of its
mobile app as a data collecting tool. Considered as human
subject research in Switzerland, a reader friendly informed
e-consent is requested from potential participants. Because we
did not have access to additional REC evaluations, further
studies are needed to determine how RECs from different
countries debated the ethical issues. It is also well known that
national RECs, as well as RECs within the same country, may
assess and balance risk-benefit ratios differently. These
divergences concerning the evaluation of similar Influenzanet
projects in different countries could interfere with the
harmonization of ethical approaches. Thus, we suggest more
transparency in terms of ethical issues related to this type of
technology-driven public health research. For instance, project
leaders of national Influenzanet platforms could publish a
summary of how RECs evaluated and debated the ethical issues
of their respective studies (eg, if their studies fall under the
category of human subject research and, thereby, need informed
consent procedures, etc). Such transparency could help to
harmonize the ethical approaches to be adopted by the country
platforms even further.
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REC approvals were not sought for the Belgian-Dutch (De Grote
Griepmeting) and Danish (Influmeter) platforms (Influmeter,
email communication, August 10, 2017) [6,20,21]. However,
their studies abided by their national legislation on privacy and
personal data protection (Influmeter, email communication,
August 10, 2017) [6,20,21,46]; for instance, the De Grote
Griepmeting privacy regulation was approved by the Dutch
Data Protection Authority [21]. According to the Belgian and
Dutch legislations, these are observational studies because no
physical or psychological intervention is intended on participants
[6,21,47]. Concerning Influmeter, the Danish platform is
exempted from the REC approval for the following reasons: the
Danish Data Protection Agency does not consider emails
exchanged between study participants and Influmeter to be
sensitive personal information; there is an automatic implicit
consent from study participants because of its voluntary nature
even if sensitive information is gathered (eg, health and
coarse-grained geographical data); and the data manager of
Influmeter, Statens Serum Institute that hosts a large proportion
of Danish health data [48] received a broad permission from
the Danish Data Protection Agency (record number:
2008-54-0474), which covers the surveillance of infectious
diseases and identifiable sensitive information gathered by
Influmeter (Influmeter, email communication, September 7,
2017) [20].
Another ethical issue arises in Influenzanet owing to the ability
of participants to record personal data on other household
members (eg, the elderly persons and children). Gathering data
on underrepresented age groups is important, specifically, when
they are the ones most vulnerable to influenza in terms of
morbidity and mortality [5]. However, it is difficult to verify
whether these family members, in particular, are legally
competent and could provide consent themselves, having
expressed their will for their personal information to be recorded
by the participating family member. It would be interesting to
evaluate through future research whether RECs have considered
this issue or have simply considered the data collected from
other family members to be anonymous and, thus, not
identifiable.
Informed e-consent was gathered from study participants from
all platforms with the only exceptions being the Belgian and
Dutch platforms, which are mirror websites of each other (De
Grote Griepmeting, email communication, January 10, 2018).
It can be argued that there is an automatic implicit consent for
Belgian and Dutch participants because registration to the study
is voluntary. The Belgium-Dutch platforms [16] might consider
providing an informed e-consent option to their participants in
an attempt to harmonize consent practices across the Consortium
if ever they resume their activities in the future. However, we
noted that it is not clear whether informed consent was legally
necessary in Belgium (“Law on experiments involving the
human subject” of May 2004) and the Netherlands because of
the observational natures of their studies (De Grote Griepmeting,
the Netherlands, email communication, January 10, 2018)
[6,21,47]. Indeed, the Belgian and Dutch legislations
acknowledge the need for informed consent for interventional
studies because of the potential physical or psychological harm
to participants [6,21,47], but the legislations do not clearly define
how broad the category of observational studies is; for instance,
a detailed questionnaire revealing some very personal
information can be seen as an intervention in the Netherlands
[49]. Nonetheless, it is important to understand the shift from
typical physical or psychological harm seen in medical research
to informational harm in public health research involving
Web-based communities of volunteer citizens or big data (eg,
data discrimination) with the latter having potential
repercussions on the physical and mental states of study
participants (eg, stigmatization and discrimination for health
insurance coverage) [50,51].
Critics might say that e-consent gathered from Influenzanet
participants does not represent valid informed consent because
researchers cannot control that participants read and understood
the information. Although information on studies is available
on their respective websites, participants usually have to look
at different sections of the website to gather pertinent
information on the study (eg, its goals, privacy policies, etc),
which is tedious and unlikely to be read in detail. The Swiss
legislation requires researchers to ensure that participants have
understood all the information (provided in the written
information form) through personal contact. According to the
Ethics Guidelines for Internet-Mediated Research by the British
Psychological Society, a valid consent can be assumed if there
is an information sheet defining the study objectives and exact
nature of questions before filling in the questionnaire, including
a check box at its beginning and end where participants can tick
in to give their explicit consent [52]. In addition, the Society
recommends using a proper wording for “I agree” statements
to encourage participants to read the information sheet, which
should also include their rights to withdraw from the study at
any time in a user friendly manner [52]. The Consortium could
follow these guidelines to enhance its e-consent procedures. It
is important to ensure that participants agreed (by clicking on
an “I agree” checkbox) to the terms, conditions, and privacy
policies listed on the informed consent sheet before being
allowed to fill in the questionnaire. Such measures should be
taken to ensure the validity of the informed consent from
participants and for harmonization purposes, a standard
information sheet could be used throughout the Consortium.
Personal data protection was ensured throughout the Consortium
because participant data are pseudonymized, that is, participants’
personal identifiers are replaced with pseudonyms. Furthermore,
any data that are shared with the public through the Web portal
are fully anonymized and highly aggregated [14]. As to the
anonymized data shared with members of the Consortium, it
can be aggregated or not depending on whether the national
partner who owns the data agrees to the request. It is also worth
noting that sharing of Influenzanet data with internal and
external researchers should not pose a priori any legal barriers
because the General Data Protection Regulation of the European
Parliament and the Council will not apply to data being rendered
anonymous, that is, the information is not linked to an identified
or identifiable natural person (Recital 26) and shared for research
and statistical purposes [53]. From information gathered on
some Influenzanet platforms (ie, France and Switzerland), it
appears that linked anonymization [54] is involved in ensuring
data protection, whereby participants’ email addresses and
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pseudonyms are stripped from the gathered health-related data
before analysis and stored separately. It will be difficult to
conclude how challenging or easy it could be to reidentify
participants directly or indirectly from specific combination of
variables (which are anonymous if considered in isolation but
permit the identification if several of them are combined), in
particular for vulnerable groups where privacy risks are higher
[48] or groups with rare variable entries, for instance, large
household compositions with >6 persons (that only account for
2% of households in the European Union [55]).
Our results show that there is a need to harmonize consent
requirements and practice throughout the Consortium because
differences in the abovementioned national consent requirements
could be the source of obstacles for the next generation of data
collection, which may include collection and sharing of more
sensitive data on a larger scale. Thus, these differences could
hinder future productive cross-national collaboration, which
will be detrimental to research and quality disease surveillance.
The consent requirements and practice could be harmonized
through international or European Union regulations. However,
this could take some time; for instance, General Data Protection
Regulation aims to harmonize data protection laws within the
28 European Union Member States to ensure an equivalent level
of protection and freedoms of individuals within the European
Union. At the same time, it will protect cross-border flows of
personal data on European Union citizens to international
organizations or third countries [56,57]. A quicker
harmonization alternative would be for all national platforms
of Influenzanet to use the strictest consent requirements and
practice currently used by one of their platforms to find common
ground.This particular platform would then be used as a
benchmark for other country platforms to harmonize their
practices.
Limitations
Only English-language papers were screened for this study for
practical reasons. It is, thus, possible that pertinent papers in
other languages were omitted but they could have provided
better insight into how issues related to research ethics are being
handled by the Influenzanet Consortium. In addition, most of
our conclusions are based on the gathered literature, and our
interpretations might be biased by the incomplete reporting of
all ELSI components in some publications as a matter of space
or pertinance to their study objectives. Consequently, despite
our collaboration with the Consortium to verify our claims, we
cannot guarantee that our interpretations are error free. Another
limitation is that we do not have access to projects’ evaluation
reports from RECs (except for Switzerland) to understand how
they judge and approve such research projects. This would have
been beneficial to the understanding of national differences in
project evaluation by RECs, which could then serve as the basis
for further harmonization of these ethical approaches.
Conclusions
Epidemics forecasting activities such as Influenzanet are
beneficial. Harmonized criteria for dealing with ethical issues
are urgently needed internationally to ensure comparability of
data and maximize participants’ trust. Approaches used in
handling issues related to research ethics by different
Influenzanet platforms seem to be similar in many, although
not all, ELSIs at present. Thus, harmonizing ethical requirements
across the Consortium is feasible and could be achieved through
the adoption of the strictest ethical requirements and practice
currently used by one platform across the Consortium.
Nonetheless, despite being similar, it does not automatically
mean that these ethical approaches are adequately regulated.
We recommend more transparency in terms of ethical issues
related to this type of technology-driven public health research.
These transparency modifications related to the current ELSIs
of Influenzanet will help to build trust among the members of
the general public, in particular, if they are properly informed
about the expected benefits and potential risks their participation
entails; this will prevent any decline in participation, which
might be triggered by mediatization, including exaggeration,
of the risks of public health surveillance using Web-based
communities of volunteer citizens.
Moreover, this type of research has the potential to save many
lives in the future because it has proven through its flexibility,
easy implementation, and adaptability to different countries’
requirements for data collection to serve as a potentially effective
and relatively low-cost surveillance tool for other diseases of
public health importance (eg, Middle East respiratory syndrome
or Ebola) [12,17]. These characteristics could allow Influenzanet
to be deployed in low- and middle-income countries to monitor
emerging and reemerging infectious diseases [17].
Our suggested harmonization measures and approach for data
gathering and ethical requirements for Influenzanet apply to
other Influenzanet-like systems. Moreover, we also suggest that
such systems increase the validity of their informed e-consent
procedures by following the excellent ethical guidelines
provided by the British Psychological Society. Such measures
will further increase the benefits Influenzanet and
Influenzanet-like systems could bring to society by promoting
the comparability of data and safeguarding participants’ trust
on which they rely almost completely for data collection. These
will ensure that Influenzanet-like systems are making even
greater substantial contributions to global public health and
reduce the health inequalities in societies worldwide through
better targeting of public health interventions in line with the
concept of precision global health in the digital age [58].
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